Комбинированная терапия ипратропиумом и β₂-агонистами при обострении хронической обструктивной болезни легких

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Last updated 2006. www.goldcopd.org/.

2. O'Donnell D.E., Parker C.M. COPD exacerbations: Pathophysiology. Thorax 2006; 61: 354–361.

3. Rodríguez0Roisin R. COPD exacerbations: management. Thorax 2006; 61: 535–544.

4. Duffy N., Walker P., Diamante F. et al. Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Thorax 2005; 60: 713–717.

5. Brown C.D., McCrory D., White J. Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2001; 1: CD002984. DOI: 10.1002/14651858.CD002984.

6. Cuvelier A., Muir J.F., pour le groupe multicentrique. Apport de la nébulisation dans les exacerbations des bronchopneumopathies chroniques obstructives: place des anticholinergiques. Ann. Fr. Anesth. Réanim. 1998; 17 (suppl. 2): 48–51.

7. Karpel J.P., Pesin J., Greenberg D., Gentry E. A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. Chest 1990; 98: 835–839.

8. Bach P.B., Brown C., Gelfand S.E., McCrory D.C. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann. Intern. Med. 2001; 134: 600–620.

9. Чучалин А.Г. (ред.). Хроническая обструктивная болезнь легких: Практ. руководство для врачей. М.; 2004. 1–64.

10. Russi E.W., Leuenberger Ph., Brandli O. et al. Management of chronic obstructive pulmonary disease: the Swiss guidelines Official Guidelines of the Swiss Respiratory Society. Swiss. Med. Wkly 2002; 132: 67–78.

11. COPD Guideline Working Group of the South African Thoracic Society. Guideline for the Management of Chronic Obstructive Pulmonary Disease (COPD): 2004 Revision. S. Afr. Med. J. 2004; 94: 559–575.

12. Willaert W., Daenen M., Bornans P. et al. What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Eur. Respir. J. 2002; 19: 928–935.

13. Guerin C., Chevre A., Dessirier P. et al. Inhaled fenoterolipratropium bromide in mechanically ventilated patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 159: 1036–1042.

14. Авдеев С.Н. Роль антихолинергических препаратов при обструктивных заболеваниях легких. Consilium Medicum 2002; 4 (9): 478–485.

15. McCrory D.C., Brown C.D. Anticholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2003; 1: CD003900. DOI: 10.1002/14651858.CD003900.

16. Shrestha M., O'Brien T., Haddoux R. et al. Decreased duration of emergency department treatment of chronic obstructive pulmonary disease exacerbation with the addition of ipratropium bromide to β-agonist therapy. Ann. Emerg. Med. 1991; 20: 1206–1209.

17. Fernandez A., Muñoz J., Calle B. et al. Comparison of one versus two bronchodilators in ventilated COPD patients. Int. Care Med. 1994; 20: 199–202.

18. Rebuck A.S., Chapman K.R., Abboud R. et al. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airway disease in the emergency room. Am. J. Med. 1987; 82: 59–64.

19. O'Driscoll B.R., Taylor R.J., Horsley M.G. et al. Nebulized salbutamol with and without ipratropium bromide in acute airflow obstruction. Lancet 1989; 2: 1418–1420.

20. Patrick D.M., Dales R.E., Stark R.M. et al. Severe exacerbations of COPD and asthma. Chest 1990; 98: 295–297.

21. Moayyedi P., Congleton J., Page R.L. et al. Comparison of nebulized salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. Thorax 1995; 50: 834–837.

22. Koutsogiannis Z., Kelly A. M. Does high dose ipratropium bromide added to salbutamol improve pulmonary function for patients with chronic obstructive airways disease in the emergency department? Aust. N. Z. Med. J. 2000; 30: 41–47.

23. Авдеев С.Н., Нуралиева Г.С., Батын С.З. и др. Эффективность комбинированной терапии ингаляционными β2 -агонистами и антихолинергическими препаратами при тяжелом обострении хронической обструктивной болезни легких: рандомизированное контролируемое исследование. Пульмонология 2007; 3: 56–65.

24. O'Donnell D.E., Laveneziana P. The clinical importance of dynamic lung hyperinflation in COPD. J. COPD 2006; 3: 219–232.

25. Parker C.M., Voduc N., Aaron S.D. et al. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur. Respir. J. 2005; 26: 420–428.

26. Stevenson N.J., Walker P.P., Costello R.W. et al. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med 2005; 172: 1510–1516.

27. Nuralieva G., Avdeev S., Chuchalin A. Time course and recovery of respiratory muscles strength in acute exacerbation of COPD. Eur. Respir. J. 2005; 26 (suppl. 49): abstr. 2341.

28. Jenkins C.R., Chow C.M., Fisher B.L., Marlin G.E. Comparison of ipratropium bromide and salbutamol by aerosolized solution. Aust. N. Z. J. Med. 1981; 11: 513–516.

29. Gross N.J., Petty T.L., Friedman M. et al. Dose response to ipratropium as a nebulised solution in patients with chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1989; 139: 1188–1191.

30. Karpel J.P. The use of anticholinergic drugs in acute exacerbations of chronic obstructive pulmonary disease. In: Gross N.J., ed. Anticholinergic therapy in obstructive airways disease. Franklin Scientific Publications; London: 1993; 145–154.

31. Nair S., Thomas E., Pearson S.B., Henry M.T. A randomized controlled trial to assess the optimal dose and effect of nebulized albuterol in acute exacerbations of COPD. Chest 2005; 128: 48–54.

32. Gross N.J., Bankwala Z. Effects of an anticholinergic bronchodilator on arterial blood gases of hypoxemic patients with chronic obstructive pulmonary disease, comparison with a beta-adrenergic agent. Am. Rev. Respir. Dis. 1987; 136: 1091–1094.

33. Centanni S., Santus P., Casanova F. et al. Bronchodilating effect of oxitropium bromide in heart disease patients with exacerbations of COPD: double-blind, randomized, controlled study. Respir. Med. 2002; 96: 137–141.

34. Cooper C.B., Tashkin D.P. Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease. Br. Med. J. 2005; 330: 640–644.

35. Celli B.R., MacNee W., committee members of ATS / ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932–946.

36. Авдеев С.Н., Нуралиева Г.С., Чучалин А.Г. Эффективность терапии препаратами ипратропия при обострении хронической обструктивной болезни легких у больных, регулярно принимающих тиотропий. Пульмонология 2008; 1: 62–68.